MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes

Table 1

Clinical characteristics of 146 patients with limited disease-small cell lung cancer.

Variables	(%)	5yOS
Gender
Male	104 (71.2%)	33.0%	0.065
Female	42 (28.8%)	47.2%
Age
≤60	95 (65.1%)	43.0%	0.015
>60	51 (34.9%)	30.8%
KPS
≥90	61 (41.8%)	47.5%	0.009
<90	85 (58.2%)	33.1%
Location
Left lobe	69 (47.3%)	39.3%	0.987
Right lobe	77 (52.7%)	37.8%
Smoking
Yes	96 (65.8%)	35.7%	0.088
No	50 (34.2%)	40.1%
Charlson comorbidity index
≤3	130 (89.0%)	41.7%	0.030
4-5	13 (8.9%)	19.5%
6-7	3 (2.1%)	0%
Weight loss
With	27 (18.5%)	51.3%	0.393
Without	119 (81.5%)	35.2%
AJCC stage
IA	1 (0.7%)	100.0%	0.573
IB	2 (1.4%)	0%
IIA	5 (3.4%)	NA
IIB	4 (2.7%)	NA
IIIA	68 (46.6%)	41.7%
IIIB	66 (45.2%)	34.9%
Treatment modality
Concurrent	80 (54.8%)	46.8%	0.401
Sequential	66 (45.2%)	31.2%
Chemotherapy cycles
<4	9 (6.2%)	NA	0.382
4–6	126 (86.3%)	40.2%
>6	11 (7.5%)	38.6%
Radiotherapy dose
<60	46 (30.7%)	39.3%	0.525
≥60	100 (69.3%)	39.9%
PCI
With	63 (43.2%)	62.1%
Without	83 (56.8%)	23.1%

OS: overall survival; AJCC: American Joint Committee on Cancer; PCI: prophylactic cranial irradiation.